Skip to main content
SpringerLink
Log in

FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma

  • Review Article
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

Optimal lymphoma management requires reliable assessment of response, both during and after therapy. Positron emission tomography with computerized tomography (PET/CT) combines functional and anatomical imaging and provides the most sensitive and accurate method for lymphoma imaging. New guidelines for lymphoma imaging and recently revised criteria for lymphoma staging and response assessment recommend PET/CT for both staging, treatment monitoring and response evaluation in all 2-[18F]fluor-2-deoxyglucose (FDG)-avid lymphomas, while CT remains the method of choice for non-FDG-avid histologies. Since interim PET imaging has high prognostic value in lymphoma, a number of trials investigate PET-based, response-adapted lymphoma therapy. PET response is the main determinant of final treatment evaluation according to the new response criteria but PET/CT has little or no role in routine surveillance imaging, which has questionable value in general. This review presents from a clinical point of view the evidence for the use of PET/CT in malignant lymphoma during and after therapy. The reader is given an overview of the current PET-based interventional Hodgkin and non-Hodgkin lymphoma trials and an insight into possible future developments in the field, including new PET tracers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Notes

  1. EORTC: European Organisation for the Research and Treatment of Cancer, GELA: Groupe des Etudes des Lymphomes de l’Adulte, FIL: Fondazione Italiana Linfomi.

  2. GITIL: Gruppo Italiano Therapie Innovative nei Linfomi, RATHL: Response-Adapted Therapy in Hodgkin Lymphoma.

References

  1. Flowers CR, Armitage JO (2010) A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk 10(6):414–423

    Article  PubMed  Google Scholar 

  2. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, et al (2014) The role of imaging in the staging and response assessment of lymphoma: consensus of the ICML Imaging Working Group. J Clin Oncol 32(27):3048–3058

    Article  PubMed  Google Scholar 

  3. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068

    Article  PubMed  Google Scholar 

  4. (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 329(14):987–994

  5. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258–1265

    Article  CAS  PubMed  Google Scholar 

  6. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474–2479

    Article  CAS  PubMed  Google Scholar 

  7. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558–565

    Article  CAS  PubMed  Google Scholar 

  8. Rankin SC (2003) Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 30(Suppl 1):S56–S64

    Article  PubMed  Google Scholar 

  9. Armitage JO, Weisenburger DD, Hutchins M, Moravec DF, Dowling M, Sorensen S et al (1986) Chemotherapy for diffuse large-cell lymphoma—rapidly responding patients have more durable remissions. J Clin Oncol 4(2):160–164

    CAS  PubMed  Google Scholar 

  10. Gupta RK, Gospodarowicz MK, Lister TA (1999) Clinical evaluation and staging. In: Mauch P, Armitage JO, Diehl V, Hoppe R, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams and Wilkins, Philadelphia, pp 223–240

    Google Scholar 

  11. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P et al (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85(6):613–618

    CAS  PubMed  Google Scholar 

  12. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma-comparison with CT. Leuk Lymphoma 39(5–6):543–553

    Article  CAS  PubMed  Google Scholar 

  13. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T et al (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13(9):1356–1363

    Article  CAS  PubMed  Google Scholar 

  14. Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GW, Teule GJ et al (1993) Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 34(10):1706–1710

    CAS  PubMed  Google Scholar 

  15. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43(8):1018–1027

    PubMed  Google Scholar 

  16. Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H et al (2004) Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 31(1):22–28

    Article  PubMed  Google Scholar 

  17. Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16(9):1514–1523

    Article  CAS  PubMed  Google Scholar 

  18. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K et al (2005) [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106(4):1376–1381

    Article  CAS  PubMed  Google Scholar 

  19. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T et al (2006) FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107(11):2678–2687

    Article  PubMed  Google Scholar 

  20. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS (2009) High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol 20(2):309–318

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16(7):1160–1168

    Article  CAS  PubMed  Google Scholar 

  22. Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M et al (2010) 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 51(9):1337–1343

    Article  CAS  PubMed  Google Scholar 

  23. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52–59

    Article  CAS  PubMed  Google Scholar 

  24. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I et al (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 91(4):475–481

    PubMed  Google Scholar 

  25. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M et al (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian–Danish study. J Clin Oncol 25(24):3746–3752

    Article  CAS  PubMed  Google Scholar 

  26. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M et al (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99(6):1107–1113

    Article  PubMed Central  PubMed  Google Scholar 

  27. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M et al (2013) International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 54(5):683–690

    Article  CAS  PubMed  Google Scholar 

  28. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50(8):1257–1260

    Article  PubMed  Google Scholar 

  29. Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M (2014) In-vivo treatment sensitivity testing with PET/CT after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol 32(25):2705–2711

    Article  PubMed  Google Scholar 

  30. Simontacchi G, Filippi AR, Ciammella P, Buglione M, Saieva C, Magrini SM et al (2015) Interim PET after two ABVD cycles in early-stage Hodgkin lymphoma: outcomes following the continuation of chemotherapy plus radiotherapy. Int J Radiat Oncol Biol Phys 92(5):1077–1083

    Article  PubMed  Google Scholar 

  31. Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F et al (2015) The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 90(6):499–503

    Article  CAS  PubMed  Google Scholar 

  32. Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K et al (2012) Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma 53(1):64–70

    Article  CAS  PubMed  Google Scholar 

  33. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21(18):3431–3439

    Article  PubMed  Google Scholar 

  34. Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD et al (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554

    Article  PubMed  Google Scholar 

  35. Johnson PWM, Federico M, Fossa A, O’Doherty MJ, Roberts T, Stevens L et al (2015) Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study. Hematol Oncol 33:102–103

    Article  Google Scholar 

  36. Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK et al (2007) Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 48(8):1548–1555

    Article  CAS  PubMed  Google Scholar 

  37. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H et al (2012) Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol 30(35):4317–4322

    Article  CAS  PubMed  Google Scholar 

  38. Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL (2011) 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 52(3):386–392

    Article  PubMed Central  PubMed  Google Scholar 

  39. Moskowitz CH, Schoder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS et al (2010) Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 28(11):1896–1903

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A et al (2009) Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 50(4):527–533

    Article  PubMed  Google Scholar 

  41. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C et al (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118(1):37–43

    Article  CAS  PubMed  Google Scholar 

  42. Fludeoxyglucose F 18 positron emission tomography in predicting risk of relapse in patients with non-Hodgkin’s lymphoma who are undergoing combination chemotherapy with or without autologous stem cell or bone marrow transplant. https://clinicaltrials.gov/ct2/show/NCT00238368. Accessed 10 Aug 2015

  43. Therapy for patients with untreated age-adjusted international prognostic index low-intermediate risk, high-intermediate risk, or high risk diffuse large B cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT00712582. Accessed 10 Aug 2015

  44. FDG-PET-stratified R-DICEP and R-Beam/ASCT for diffuse large B-cell lymphoma (PET Chop). https://clinicaltrials.gov/ct2/show/NCT00530179. Accessed 10 Aug 2015

  45. A study of two associations of rituximab and chemotherapy, with a PET-driven strategy, in lymphoma (LNH2007-3B). https://clinicaltrials.gov/ct2/show/NCT00498043. Accessed 10 Aug 2015

  46. Duehrsen U, Hüttmann A, Müller S, Hertenstein B, Kotzerke J, Mesters R et al (2014) Positron emission tomography (PET) guided therapy of aggressive lymphomas—a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial). Blood 124(21):391

    Google Scholar 

  47. Sehn LH, Hardy ELG, Gill KK, Al Tourah AJ, Shustik J, Macpherson NA et al (2014) Phase 2 trial of interim pet scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood 124(21):392

    Google Scholar 

  48. Study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non Hodgkin’s lymphoma CD20+. https://clinicaltrials.gov/ct2/show/NCT01285765. Accessed 10 Aug 2015

  49. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244

    CAS  PubMed  Google Scholar 

  50. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91(4):522–529

  51. Terasawa T, Nihashi T, Hotta T, Nagai H (2008) 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive Non-Hodgkin’s lymphoma: a systematic review. J Nucl Med 49(1):13–21

    Article  PubMed  Google Scholar 

  52. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586

    Article  PubMed  Google Scholar 

  53. Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J et al (2007) Hodgkin lymphoma: response assessment by revised International Workshop Criteria. Leuk Lymphoma 48(8):1539–1547

    Article  PubMed  Google Scholar 

  54. Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A et al (2011) Positron emission tomography–computed tomography (PET–CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET–CT in a subset of PRIMA trial participants. J Clin Oncol 29(23):3194–3200

    Article  PubMed  Google Scholar 

  55. Zinzani PL, Musuraca G, Alinari L, Fanti S, Tani M, Stefoni V et al (2007) Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 7(4):291–295

    Article  PubMed  Google Scholar 

  56. Tychyj-Pinel C, Ricard F, Fulham M, Fournier M, Meignan M, Lamy T et al (2014) PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging 41(3):408–415

    Article  PubMed  Google Scholar 

  57. Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C et al (2014) The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol 25(2):442–447

    Article  CAS  PubMed  Google Scholar 

  58. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799

    Article  CAS  PubMed  Google Scholar 

  59. Savage KJ, Connors JM, Klasa RJ, Hoskins P, Shenkier TN, Gascoyne RD et al (2011) The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. J Clin Oncol 29(15 suppl.):8034 (ASCO Annual Meeting Abstracts Part 1)

  60. Martelli M, Ceriani L, Zucca E, Zinzani PL, AsJM Ferreri, Vitolo U et al (2014) [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 32(17):1769–1775

    Article  PubMed  Google Scholar 

  61. Randomized, open-label two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after rituximab containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT01599559. Accessed 10 Aug 2015

  62. Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD et al (2013) Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol 31(S1):137

    Google Scholar 

  63. Hamlin PAZ (2003) Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102(6):1989–1996

    Article  CAS  PubMed  Google Scholar 

  64. Weeks JC, Yeap BY, Canellos GP, Shipp MA (1991) Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 9(7):1196–1203

    CAS  PubMed  Google Scholar 

  65. Guppy AE, Tebbutt NC, Norman A, Cunningham D (2003) The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma 44(1):123–125

    Article  CAS  PubMed  Google Scholar 

  66. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD (2006) Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 17(6):909–913

    Article  CAS  PubMed  Google Scholar 

  67. Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH et al (2012) Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Ann Hematol 91(11):1741–1745

    Article  PubMed  Google Scholar 

  68. El Galaly TC, Mylam KJ, Boegsted M, Brown P, Rossing M, Gang AO et al (2014) Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol 89(6):575–580

    Article  PubMed  Google Scholar 

  69. El Galaly T, Prakash V, Christiansen I, Madsen J, Johansen P, Boegsted M et al (2011) Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma 52(4):597–603

    Article  PubMed  Google Scholar 

  70. Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P et al (2009) Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 27(11):1781–1787

    Article  PubMed  Google Scholar 

  71. Cheah CY, Hofman MS, Dickinson M, Wirth A, Westerman D, Harrison SJ et al (2013) Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109(2):312–317

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC et al (2012) High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma 53(6):1113–1116

    Article  PubMed  Google Scholar 

  73. Cheah C, Dickinson M, Hofman M, George A, Ritchie D, Prince HM et al (2014) Limited clinical benefit for surveillance PET–CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. Ann Hematol 93(7):1193–1200

    Article  CAS  PubMed  Google Scholar 

  74. Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM et al (2013) Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol 88(5):400–405

    Article  CAS  PubMed  Google Scholar 

  75. Petrausch U, Samaras P, Veit-Haibach P, Tschopp A, Soyka JD, Knuth A et al (2010) Hodgkin’s lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 21(5):1053–1057

    Article  CAS  PubMed  Google Scholar 

  76. Torrey MJ, Poen JC, Hoppe RT (1997) Detection of relapse in early-stage Hodgkin’s disease: role of routine follow-up studies. J Clin Oncol 15(3):1123–1130

    CAS  PubMed  Google Scholar 

  77. Radford JA, Eardley A, Woodman C, Crowther D (1997) Follow up policy after treatment for Hodgkin’s disease: too many clinic visits and routine tests? A review of hospital records. BMJ 314(7077):343–346

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Dryver ET, Jernstrom H, Tompkins K, Buckstein R, Imrie KR (2003) Follow-up of patients with Hodgkin’s disease following curative treatment: the routine CT scan is of little value. Br J Cancer 0 AD 89(3):482–486

  79. El Galaly TC, Mylam KJ, Brown P, Specht L, Christiansen I, Munksgaard L et al (2012) Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica 97(6):931–936

    Article  PubMed Central  PubMed  Google Scholar 

  80. Lee AI, Zuckerman DS, van den Abbeele AD, Aquino SL, Crowley D, Toomey C et al (2010) Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer 116(16):3835–3842

    Article  PubMed  Google Scholar 

  81. Picardi M, Pugliese N, Cirillo M, Zeppa P, Cozzolino I, Ciancia G et al (2014) Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission—a randomized trial of routine surveillance imaging procedures. Radiology 272(1):262–274

    Article  PubMed  Google Scholar 

  82. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol–a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18(16):3025–3030

    CAS  PubMed  Google Scholar 

  83. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP et al (1998) Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: value of augmented preparative regimens—a Southwest Oncology Group trial. J Clin Oncol 16(1):48–55

    CAS  PubMed  Google Scholar 

  84. Mocikova H, Pytlik R, Markova J, Steinerova K, Kral Z, Belada D et al (2011) Pre-transplant positron emission tomography in relapsed Hodgkin lymphoma patients. Leuk Lymphoma 52(9):1668–1674

    Article  PubMed  Google Scholar 

  85. Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN et al (2011) Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 17(11):1646–1652

    Article  PubMed Central  PubMed  Google Scholar 

  86. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD et al (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116(23):4934–4937

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  87. Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G et al (2002) Positron emission tomography with [18F]2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 16(2):260–267

    Article  CAS  PubMed  Google Scholar 

  88. Terasawa T, Dahabreh IJ, Nihashi T (2010) Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist 15(7):750–759

    Article  PubMed Central  PubMed  Google Scholar 

  89. Dickinson M, Hoyt R, Roberts AW, Grigg A, Seymour JF, Prince HM et al (2010) Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 150(1):39–45

    PubMed  Google Scholar 

  90. Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B et al (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant 30(2):103–111

    Article  CAS  PubMed  Google Scholar 

  91. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102(1):53–59

    Article  CAS  PubMed  Google Scholar 

  92. Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME et al (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124(2):608–613

    Article  PubMed  Google Scholar 

  93. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119(7):1665–1670

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark

    Martin Hutchings

  2. PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King’s College London, King’s Health Partners, St. Thomas’ Hospital, London, SE1 7EH, UK

    Sally Barrington

  3. Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark

    Martin Hutchings

Authors
  1. Martin Hutchings
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sally Barrington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Hutchings.

Ethics declarations

Conflict of interest

Martin Hutchings has no conflicts of interest to declare. Sally Barrington has no conflicts of interest to declare.

Research involving human participants and/or animals

This article does not contain any studies with human or animal subjects performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hutchings, M., Barrington, S. FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. Clin Transl Imaging 3, 271–281 (2015). https://doi.org/10.1007/s40336-015-0134-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-015-0134-y

Keywords

Search

Navigation